Starving the Sprouts: Cutting a Single Protein Slows Blinding Eye Disease in Mice

Diabetic retinopathy is one of the most feared complications of diabetes, and for good reason. It is a leading cause of blindness in working-age adults, and its most destructive phase is driven by the runaway growth of fragile new blood vessels across the light-sensitive retina. A study published on 14 October 2026 in Cell Death Discovery now points to an unexpected culprit in this process: lipocalin-2, a small secreted protein better known for its roles in inflammation and iron transport. The work, led by Tingfang Mei, Haohan Yang and Haoyu Zuo under the supervision of Chengguo Zuo and Ling Zhao at Sun Yat-sen University’s Zhongshan Ophthalmic Center in Guangzhou, suggests that blocking this protein could starve pathological blood vessel growth of the energy it needs to invade the retina.

The research team approached the problem from a perspective that has been reshaping the field for the past decade. Diabetic retinopathy is increasingly understood not simply as a plumbing failure of tiny blood vessels, but as a neurovascular degenerative disease in which early neuronal dysfunction, chronic metabolic stress and progressive microvascular damage reinforce one another. Within that framework, the metabolic state of endothelial cells, the thin layer of cells lining the interior of blood vessels, becomes a central question. Growing new vessels is an energetically expensive enterprise, and endothelial cells must ramp up their metabolism to proliferate, migrate and remodel tissue.

Lipocalin-2, often abbreviated LCN2, entered the picture because clinical studies had already reported elevated levels of the protein in patients with diabetic retinopathy. Elevated levels of a molecule in a disease state, however, do not by themselves prove that the molecule causes the disease; it could be a bystander, a marker of tissue stress, or even a protective response. What remained poorly defined, as the authors note in their abstract, was the functional role of LCN2 in diabetic retinal vascular pathology. Answering that question required more than correlation, and the team turned to a pair of genetically engineered mouse models designed to manipulate LCN2 with precision.

The first model was an LCN2 overexpressing mouse, designated LCN2-Tg, in which the animals carry extra copies of the gene and produce abnormally high amounts of the protein throughout life. The second was the opposite experiment: an endothelium-specific LCN2 knockout, written Lcn2-fl/fl; Cdh5-CreERT2, in which the gene is deleted selectively in endothelial cells. The Cdh5-CreERT2 system uses the cadherin-5 promoter, active almost exclusively in vascular endothelium, to drive an inducible form of the Cre recombinase enzyme, allowing researchers to remove Lcn2 from blood vessel lining cells in adult animals. This specificity matters, because LCN2 is produced by many cell types, including immune cells and epithelial tissue, and a whole-body knockout would make it impossible to attribute any vascular effect to the endothelium itself.

With these tools in hand, the researchers examined how LCN2 influences retinal vascular remodeling and endothelial function under both physiological and pathological conditions. The results were striking. Loss of LCN2 in endothelial cells suppressed both the normal, developmental expansion of retinal vessels and the pathological vessel growth that mimics what happens in diabetic retinopathy. Crucially, however, the deficiency did this while preserving vascular stability. That distinction is important from a therapeutic standpoint: an ideal treatment for retinal neovascularization would prune away the destructive, leaky vessels that characterize the disease without destabilizing the healthy vasculature that the retina depends on for oxygen and nutrients.

The mechanistic heart of the paper lies in energy metabolism. When the team looked at animals and cells with elevated LCN2, they found enhanced endothelial cell energy metabolism, and this metabolic boost went hand in hand with exacerbated pathological neovascularization. In other words, LCN2 appears to act as a metabolic enabler for endothelial cells, revving up their bioenergetic machinery so they can sustain the high demands of proliferation and migration. Sprouting new capillaries requires cells to divide rapidly, crawl through surrounding tissue, and reorganize their cytoskeletons, all of which consume large quantities of ATP and biosynthetic intermediates. By amplifying metabolic capacity, LCN2 gives pathological vessels the fuel they need to advance.

The converse experiment confirmed the logic. When LCN2 was downregulated, endothelial cells showed suppressed proliferation and migration, accompanied by a restricted metabolic capacity. The cells simply lacked the energetic headroom to mount an angiogenic response. This coupling of behavior to metabolism is consistent with a broader theme in vascular biology: endothelial cells are not passive tubes but metabolically dynamic cells whose glycolytic flux, mitochondrial activity and nutrient handling directly govern whether vessels sprout, stabilize or regress. The new study places LCN2 squarely within that regulatory circuitry, identifying it as a regulator of what the authors call endothelial metabolic competence in the diabetic retina.

Why does this matter for patients? Current treatments for proliferative diabetic retinopathy rely heavily on blocking vascular endothelial growth factor, or VEGF, either through injections of anti-VEGF antibodies into the eye or through laser photocoagulation that destroys peripheral retinal tissue to reduce oxygen demand. These approaches have transformed outcomes, but they have limitations. Anti-VEGF therapy requires repeated injections, some patients respond incompletely, and there are lingering concerns about the long-term effects of suppressing a factor that also supports neuronal and vascular health in the retina. A target that operates through a different axis, in this case cellular energy metabolism rather than growth factor signaling, could complement existing therapies or offer an alternative for patients who do not respond well to VEGF blockade.

The authors are careful about the translational implications, and appropriately so. Their conclusion is that pathological upregulation of LCN2 contributes to retinal microvascular dysfunction, and that targeting LCN2-dependent metabolic regulation may therefore represent a potential therapeutic strategy for diabetic retinopathy. That is a long road from a mouse study. Human diabetic retinopathy unfolds over years in a metabolic environment shaped by hyperglycemia, inflammation and oxidative stress, and interventions that work in genetically defined animals do not always translate. Any future therapy would need a safe way to inhibit LCN2 in the eye, whether through antibodies, small molecules or gene-based approaches, and would need to avoid interfering with the protein’s beneficial roles in innate immunity and tissue repair elsewhere in the body.

Even so, the study adds a compelling new character to the cast of molecules implicated in diabetic eye disease, and it does so with an unusually clean experimental design that combines gain-of-function and cell-type-specific loss-of-function genetics. It also reinforces a conceptual shift with implications well beyond ophthalmology: pathological angiogenesis is not just a signaling problem but a metabolic one, and the vessels that ravage the diabetic retina can be weakened by cutting their fuel supply. For the hundreds of millions of people living with diabetes worldwide, and for the growing fraction of them who will develop retinopathy as the disease progresses, a new metabolic handle on the process is a development worth watching closely.

Subject of Research: The role of lipocalin-2 in endothelial energy metabolism and pathological angiogenesis in diabetic retinopathy

Article Title: Knockdown of lipocalin 2 alleviates ocular angiogenesis in diabetic retinopathy by lowering endothelial cell energy metabolism

Article References: Knockdown of lipocalin 2 alleviates ocular angiogenesis in diabetic retinopathy by lowering endothelial cell energy metabolism. (n.d.). https://doi.org/10.1038/s41420-026-03378-3

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03378-3

Keywords: diabetic retinopathy, lipocalin-2, angiogenesis, endothelial cells, energy metabolism, retinal vascular disease, knockout mouse models, neovascularization, metabolic regulation, ophthalmology, vascular biology, Cell Death Discovery